Published in Medical Patent Week, April 29th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genentech, Inc.
Report 1: Genentech, Inc. (NYSE:DNA) announced that the U.S. Patent and Trademark Office issued a final Office action in its reexamination of the Cabilly, et al. U.S. Patent No. 6,331,415 ('415 patent) and rejected the patentability of the claims of the '415 patent. Genentech plans to respond to the final Office action within the next several months and, if necessary, appeal the decision through all appropriate means of review within the Patent Office and the courts. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week